[5]Tolaney SM,Tarantino P,Graham N,et al.Adjuvant paclitaxel and trastuzumab for node-negative,HER2-positive breast cancer:final 10-year analysis of the open-label,single-arm,phase 2 APT trial.Lancet Oncol.2023 Mar;24(3):273-285. [6]Tolaney SM,Barry WT,Dang CT,et al.Adjuvant paclitaxe...
5. Nitz U, Gluz O, Christgen M, et al. De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR- phase II trial: efficacy, safety, and predictive markers fo...
[1]Cronin KA, Harlan LC, Dodd KW, Abrams JS, Ballard-Barbash R. Population-based estimate of the prevalence of HER-2 positive breast cancer tumors for early stage patients in the US. Cancer Invest (2010) 28(9):9...
Abramson V.G., Arteaga C.L., Spring L.M., Waks A.G., et al. Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab. Cancer Discov. 2021;11:2474–2487. doi: 10.1158/2159-8290...
Pivot X, Romieu G, Debled M, et al; PHARE trial investigators. 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial. Lancet Oncol. 2013;14(8):741-748. ...
Semiglazov V, López-Vivanco G, Jenkins V, Scotto N, Osborne S, Fallowfield L; PrefHer Study Group. Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study. Lancet Oncol. 2013 Sep;14(...
Harbeck N, Gluz O, Christgen M, et al. De-escalation strategies in human epidermal growth factor receptor 2 (HER2)-positive early breast cancer (BC): final analysis of the west German Study Group adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy re...
Did you mean “herpositive early breast cancer” ? ▾ Dictionary English-ChineseUnder construction positiveadj— 正adj · 正面adj · 阳性adj · 积极的adj · 良好adj breast cancer— 乳腺癌 breastn— 乳n · 乳房n · 胸部n · 奶子n
[31]de Haas SL,et al.Biomarker analysis from the neoadjuvant KRISTINE study in HER2-positive early breast cancer(EBC)[abstract].In:Proceedings of the 2016 San Antonio Breast Cancer Symposium;2016 Dec 6-10;San Antonio,TX.Philadelphia(PA):AACR;Cancer Res 2017;77(4 Suppl):Abstract nr P6-07-...
英文标题:HER2-Directed Antibody-Drug Conjugate SHR-A1811 in the Neoadjuvant Treatment of HER2-positive Early Breast Cancer: a Prospective, Randomized, Open-label, Phase 2 Trial 报告人:李俊杰(复旦大学附属肿瘤医院) 研究内容...